Product Description.:
CONTROL ECZEMA ITCH WITH ATOPICLAIR
People with eczema have a weakened skin barrier that makes their skin easily irritated, itchy, and prone to flare up with a red rash.
Atopiclair Nonsteroidal Cream is prescribed to:
* Relieve itch ? Break the itch-scratch cycle
* Support a healthy skin barrier
* Help control eczema flares
Clinical studies have shown that people who use Atopiclair require less steroid creams and ointments to manage their eczema.
What is Atopiclair?
A unique skin-barrier repair cream for eczema:
* Relieves the itching, burning, and pain associated with eczema and allergic contact dermatitis
* Supports a healthy skin barrier to help control recurring flares
* Safe for use anywhere on the skin including face, neck, and diaper area
What makes Atopiclair unique?
In eczema, the protective barrier abilities of the skin are lost.
Moisture gets out and irritants can easily trigger itch and other
flare symptoms.
* Atopiclair significantly reduces itch
* Atopiclair supports a healthy skin barrier and has no age restriction for use
Moisturizers are used on the whole body as part of a good daily skin-care routine. Atopiclair is used only on flare-prone areas.
Important Safety Information
For external use only avoid contact with eyes.
Under the supervision of a health care professional, Atopiclair nonsteroidal cream is indicated to manage and relieve the itching, burning and pain experienced with various types of dermatoses, including atopic dermatitis and allergic contact dermatitis. Atopiclair nonsteroidal cream helps to relieve dry, waxy skin by maintaining a moist skin environment, which is beneficial to the healing process.
Atopiclair nonsteroidal cream does not contain milk, wheat, peanut or animal derivatives. Atopiclair nonsteroidal cream does contain shea butter (butyrospermum parkii), a derivative of shea nut oil (not peanut oil). Patients with a known allergy to nuts or nut oils should consult their physician before using this topical preparation.
Frequently reported adverse events in Atopiclair-treated and vehicle-treated groups were burning (6.9% vs 7.1%) and stinging (8.3% vs 2.8%).